Preclinical to first-in-human
Clarify development logic, initial regulatory path, translational evidence and first clinical decision points.
WHO WE HELP / EMERGING BIOTECH
Advance the asset without building large-company overhead
VED helps lean development teams make the next consequential choice, prepare for external scrutiny and assemble senior capability around the value-creating milestone.
VED working method
- 01Milestone
- 02Runway
- 03Readiness
01
The recurring biotech constraint
The science may be differentiated, but the team is small, the evidence is incomplete and the next decision affects financing, partnership and time. A broad consulting scope adds cost. A narrowly framed senior intervention can change the path.
Dose and expansion
Connect safety, PK/PD, activity, biomarker and agency expectations before expanding.
Registrational transition
Identify the evidence, design, operational and filing gaps before committing to the pivotal path.
Partnering or financing
Make the programme rationale, risks, dependencies and next value inflection legible to outsiders.
02
A capital-efficient sequence
- Start with a fixed Decision Sprint
- Add fractional leadership only where ongoing ownership is required
- Deploy a small expert pod around the critical deliverable
- Convert to a permanent search when the role and runway justify it
- Capture decisions and evidence in an AI-ready, controlled programme memory
Start with the constraint
What must your programme decide, prove or deliver next?
Share the situation, evidence and timing. We will propose the smallest credible first step.